Nine Companies, One Factory: What a Live Shortage Is Telling Investors About Supply Chain Risk
By Matthew Holt, Co-Founder, Collaborative Sourcing
Right now, nine pharmaceutical companies are managing a medicine shortage they didn't cause. Advanz Pharma, Adamed Pharma, Alter, Belupo, Biogaran, EGIS Pharmaceuticals, Elpen, G.L. Pharma, and Innovis Pharma each market different products, in different markets, under different brand names. According to the European Medicines Agency's shortage notice, every one of them traces back to the same single point of failure: manufacturing issues at Pharmathen International's facility in Greece.
Separately, Cipla confirmed in a stock exchange clarification that it is currently evaluating the impact on its largest US product, also manufactured at the same site.
None of these companies did anything wrong. All of them are now managing the consequences of a concentration risk that existed long before this month — it just wasn't visible until now.
This Isn't Pharmathen's First Warning
This is worth sitting with for investors specifically, because it's not the first time this exact facility has turned an operational issue into a financial one. An FDA inspection at the same Rodopi site in November 2025 resulted in nine inspectional observations — covering contamination control and sterile condition deficiencies — made public via Form 483 in January 2026. That finding escalated into a US FDA import alert restricting exports.
The consequence wasn't limited to the products directly affected. In June 2026, Partners Group Private Equity disclosed that it had written off its entire €20 million investment in Pharmathen itself. The firm stated that despite what it described as major operational turnaround initiatives over the previous year, the export restriction alone was enough to take the implied value of the investment to effectively zero.
Read together, the pattern is hard to miss: one facility, two separate regulatory findings within a year, one realised equity write-off, and now a live shortage spanning nine more companies. This isn't a one-off news story. It's what unpriced concentration risk looks like when it compounds.
Why This Matters at the Deal Table, Not Just the Plant Floor
Financial due diligence on a pharma or life sciences asset is rigorous by default — revenue quality, IP position, regulatory pathway, management track record. Supply chain due diligence, in our experience, is frequently far shallower: a list of suppliers, a check that contracts exist, a confirmation that current output meets forecast demand.
What it rarely captures is the question that actually determines downside risk: if this single facility failed an inspection tomorrow, what happens to revenue, and how long would recovery take?
That question would have flagged this exposure well before either the January 2026 FDA finding or the current shortage did. It's answerable during standard diligence — inspection history, single-source dependency, and facility concentration are all assessable pre-close, if supply chain risk is evaluated with the same rigour as financial risk rather than treated as an operational afterthought.
What This Means in Practice
For portfolio companies and deal teams, the practical version of this isn't complicated, even if the analysis behind it needs to be thorough:
Map single points of failure before you own them. Which products, and what proportion of revenue, sit behind a single manufacturing site with no qualified second source? This is answerable pre-close, not just post-acquisition.
Treat CMO/CDMO concentration as a valuation input, not a footnote. A business entirely dependent on one facility for a flagship product carries a different risk profile than one with dual-sourced or geographically diversified manufacturing — that should be reflected in price, structure, or post-close remediation plans, not discovered afterward.
Build the remediation plan before you need it. For portfolio companies already holding this exposure, the value of dual sourcing isn't theoretical — it's the difference between an inspection finding becoming a schedule delay versus becoming a write-off. Qualifying a second source is materially cheaper, at any point, than doing it during a live supply crisis.
The Broader Pattern
Pharmathen is one name, at one facility, and it's already generated two separate findings and a nine-figure write-off inside a year. It won't be the last case like this. As the industry continues to consolidate manufacturing into specialist CMOs — often for good reason, since specialisation improves quality and efficiency — the concentration risk sitting behind that trend is easy to overlook precisely because it rarely shows up until something forces it into view.
The investors who come out ahead in that environment won't be the ones who avoid CMO relationships. They'll be the ones who priced the concentration risk correctly before it became someone else's press release.
The Question Worth Asking Before the Next Deal
Before the next investment committee memo goes out, it's worth asking plainly: has anyone actually mapped what happens to this business if its primary manufacturing partner fails an inspection next quarter? If the honest answer is "not in enough detail," that's a gap worth closing before it closes itself.
Matthew Holt is Co-Founder of Collaborative Sourcing, a procurement consultancy for pharmaceutical, life sciences, and CDMO sectors. His background is in API sourcing and CMO/CDMO management, helping clients and their investors understand and de-risk supply chain concentration before it becomes a valuation event. Get in touch contact@collaborative-sourcing.com